ERBB2 and breast carcinoma: Triple negative and Her2 positive breast cancer generally respond better to neoadjuvant chemotherapy than those that are hormone receptor positive, that is basal-like and Her2 enriched respond better than luminal breast cancer [[22], [23], [24]].